Vanta Bioscience Limited (BOM:540729)
India · Delayed Price · Currency is INR 19.60
0.00 (0.00%)
At close: Sep 7, 2026
Vanta Bioscience Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 124 | 96 | 140 | 404 | 363 | 693 | |
Market Cap Growth | -15.19% | -31.51% | -65.44% | 11.30% | -47.66% | -32.61% |
Enterprise Value | 503 | 400 | 753 | 997 | 816 | 1,109 |
Last Close Price | 19.60 | 15.15 | 22.12 | 64.00 | 57.50 | 109.85 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 130.67 | 88.30 | - | - | - | 786.08 |
PS Ratio | 6.81 | 5.27 | 7.11 | 4.16 | 5.78 | 6.92 |
PB Ratio | 0.58 | 0.45 | 3.69 | 3.11 | 1.92 | 2.36 |
P/TBV Ratio | - | - | - | - | 5.25 | 3.79 |
P/OCF Ratio | - | - | - | 15.05 | - | 13.14 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 27.70 | 22.01 | 38.37 | 10.25 | 13.01 | 11.07 |
EV/EBITDA Ratio | 27.03 | 21.48 | - | 75.03 | - | 29.19 |
EV/EBIT Ratio | 79.67 | 63.32 | - | - | - | 44.66 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 1.80 | 1.80 | 18.52 | 4.70 | 3.02 | 1.53 |
Debt / EBITDA Ratio | 20.45 | 20.45 | - | 45.87 | - | 11.81 |
Net Debt / Equity Ratio | 1.79 | 1.79 | 18.47 | 4.69 | 3.02 | 1.52 |
Net Debt / EBITDA Ratio | 20.38 | 20.38 | -16.41 | 45.75 | -23.84 | 11.75 |
Net Debt / FCF Ratio | -3.14 | -3.14 | -7.67 | -84.35 | -1.95 | -3.75 |
Asset Turnover | 0.02 | 0.02 | 0.02 | 0.11 | 0.08 | 0.13 |
Inventory Turnover | - | - | 0.22 | 0.12 | 0.14 | 0.10 |
Quick Ratio | 0.23 | 0.23 | 0.26 | 0.33 | 0.12 | 0.36 |
Current Ratio | 1.20 | 1.20 | 0.58 | 0.75 | 0.86 | 1.01 |
Return on Equity (ROE) | 0.87% | 0.87% | -158.62% | -53.95% | -43.27% | 0.48% |
Return on Assets (ROA) | 0.52% | 0.52% | -6.33% | -2.33% | -3.81% | 2.05% |
Return on Invested Capital (ROIC) | 1.07% | 0.95% | -11.77% | -4.23% | -6.75% | 2.19% |
Return on Capital Employed (ROCE) | 1.20% | 1.20% | -14.60% | -5.10% | -7.60% | 3.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 0.88% | 1.13% | -34.20% | -5.73% | -17.86% | 0.13% |
FCF Yield | -97.74% | -126.45% | -65.19% | -1.78% | -80.77% | -17.16% |
Buyback Yield / Dilution | -14.38% | -14.38% | - | - | - | - |